Hepatoxicity SIG (Mar 24): Hepatotoxicity in inflammatory bowel disease: immunomodulators, biologics, and beyond-Hepatoxicity SIG: Hepatoxicity in Inflammatory Bowel Disease

Video Transcription

Video Summary

The presentation is part of the Hepatotoxicity Special Interest Group seminar series, featuring Dr. Einar Bjornsson, a renowned expert in gastroenterology and hepatology. Dr. Bjornsson discusses various types of drug-induced liver injury (DILI), focusing on cases associated with medications used for inflammatory bowel disease (IBD), such as azathioprine, infliximab, and other biologics.<br /><br />Dr. Bjornsson emphasizes the differences between types of liver injury, categorizing them into direct, idiosyncratic, and indirect hepatotoxicity. Through his extensive research and experience, he highlights the clinical features, diagnosis, and treatment strategies for managing liver injuries caused by these drugs. Specifically, he refers to infliximab and describes his study of 36 cases in Iceland, highlighting that most liver injuries are relatively mild and resolve with corticosteroids. Dr. Bjornsson also discusses the potential for switching to other TNF-alpha inhibitors following liver injury.<br /><br />Additionally, he shares data suggesting that co-treatment with methotrexate may reduce the risk of liver injury when using these drugs. The seminar also recognizes the critical role of patient monitoring, genetic factors, and treatment strategies such as corticosteroid use when addressing infliximab-induced liver injury. In conclusion, Dr. Bjornsson elaborates on the importance of understanding these hepatotoxicity profiles to effectively manage and treat patients with inflammatory bowel disease receiving these medications. The seminar closes with a Q&A session, exploring detailed clinical considerations and risk factors in treating liver injuries associated with IBD therapies.

Keywords

Hepatotoxicity

Dr. Einar Bjornsson

Drug-induced liver injury

Inflammatory bowel disease

Azathioprine

Infliximab

Biologics

Corticosteroids

TNF-alpha inhibitors

Methotrexate